Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Incannex Healthcare receives AUD 6.04m tax credit and expects a further AUD 5.1m

Incannex Healthcare has received a payment of AUD 6,039,162.43 from the Australian research and development incentive program and expects additional tax credits of AUD 5.1 million in 2026. The expected total proceeds from this non-dilutive capital therefore exceed AUD 11.1 million. The funds are intended to support further development of clinical programs such as IHL-42X and PSX-001 and capital allocation measures, including a share buyback program. » Altro su de.investing.com
Incannex starts DReAMzz study to optimise dosing of IHL-42X for obstructive sleep apnea

Incannex has begun the clinical DReAMzz crossover study to optimise dosing of IHL-42X (dronabinol/acetazolamide) for the treatment of obstructive sleep apnea. The company lists 14 identified study centres, completed manufacturing of the investigational products, and secured import/export approvals and distribution agreements to activate the sites. IHL-42X has Fast Track status with the FDA; Incannex notes rapid cash burn despite positive balance-sheet metrics and says adequate funding is critical (market capitalization: $53.8m; share price: $3.90). » Altro su de.investing.com
Incannex reactivates stock buyback program after pause

Incannex resumed its stock buyback program after a period of inactivity over the last two trading days and says it will opportunistically continue repurchasing shares. The biopharmaceutical company reports about $75 million in cash following a financing round, is debt-free and shows a very high short-term liquidity ratio (Current Ratio 48.27). The stock trades at $3.41, below the InvestingPro fair value of $4.06; as of 31.12.2025 roughly $18.5 million remained available for buybacks. Incannex stresses the decision reflects a discrepancy between market valuation and its financial position as well as progress in the clinical pipeline (including IHL-42X, PSX-001). » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo anno, INCANNEX HEALTHCARE LTD. ha registrato ricavi pari a 618,83K € e un utile netto di -12,19 Mln €

(EUR)	2023	YoY
Ricavi	618,83K	20,15%
Utile lordo	618,83K	21,13%
Utile netto	-12,19 Mln	122,65%
EBITDA	-10,79 Mln	361,24%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	8,79 Mln €
Numero di azioni	347,71 Mln
Massimo/minimo a 52 settimane	0,17 € - 0,0253 €
Dividendi	No
Beta	2,09
Rapporto P/E	-1,62
Rapporto PEG	-0,12
Rapporto P/B	0,60
Rapporto P/S	653,76

Profilo aziendale

Incannex Healthcare Limited beschäftigt sich mit der Forschung, Entwicklung und dem Verkauf von medizinischen Cannabinoidprodukten in Australien. Es bietet pharmazeutische Cannabinoidprodukte unter dem Markennamen Incannex an. Zu den Produkten des Unternehmens gehören IHL-42X, das sich in klinischen Studien der Phase II zur Behandlung von obstruktiver Schlafapnoe befindet, IHL-216A zur Behandlung von traumatischen Hirnverletzungen und IHL-675A, eine Kombination aus Hydroxychloroquin und Cannabidiol zur Vorbeugung und Behandlung von entzündlichen Lungenerkrankungen wie akutem Atemnotsyndrom, chronisch obstruktiver Lungenerkrankung, Asthma und Bronchitis sowie rheumatischer Arthritis und entzündlichen Darmerkrankungen. Es besteht eine Partnerschaft mit dem Alfred Hospital und Novotech für das klinische Programm IHL-42X zur Behandlung der obstruktiven Schlafapnoe sowie mit der Monash Trauma Group am Department of Neuroscience der Monash University zur Durchführung einer Studie über die schützende Wirkung von IHL-216A bei Gehirnerschütterungen im Sport. Das Unternehmen war früher als Impression Healthcare Limited bekannt und änderte im Juni 2020 seinen Namen in Incannex Healthcare Limited. Incannex Healthcare Limited wurde im Jahr 2001 gegründet und hat seinen Sitz in Sydney, Australien.